Dr. Dupré is a neurologist at the CHU de Québec-Laval University, a Full Professor in the Department of Medicine of the School of Medicine (Laval University), and the Director of the Neuromuscular and Neurogenetic Disease Clinic of the CHU de Québec – Université Laval.

Dr. Dupré completed his medical training at McGill University and his residency in neurology at Laval University. He completed his postdoctoral training at the Montreal Neurological Hospital and Institute and at Harvard University. In 2007, he discovered a gene (syne-1) implicated in a new form of hereditary ataxia that has since been highly recognized internationally. Dr. Dupré also played an important role in the discovery of the involvement of the TARDBP in the etiology of amyotrophic lateral sclerosis. He is now involved in several provincial, national, and international networks that contribute to the discovery of genes involved in neurological diseases. He has generated more than 100 original publications. Dr. Dupré’s remarkable achievements have earned him several awards, including the 2015 Quebec Society of Muscular Dystrophy Award – ALS component – related to his involvement in the Clinic for Neuromuscular and Neurogenetic Diseases.

The research component of the clinic has grown significantly in recent years, with the creation of the Québec Parkinson Network (rpq-qpn.ca). The network connects clinicians with basic science researchers in the field, giving access to a registry of nearly 1000 patients. In addition to his clinical program, Dr. Dupré is involved in research projects linking clinical and basic research. This is done in collaboration with Dr. François Gros-Louis, of the LOEX research center at CHU de Québec – Laval University. One of these projects aims to discover biomarkers of amyotrophic lateral sclerosis in the skin. Another important project Dr. Dupré takes part in focuses on the development of a reconstructed skin model to study neurofibromatosis. Finally, Dr. Dupré is actively collaborating with Dr. Gros-Louis to identify pathogenic mechanisms of intracranial aneurysms in the Inuit and French-Canadian populations and to develop in vitro models of the disease. This project has just been funded by CIHR for a duration of 5 years.

1401, 18e Rue
Département des sciences neurologiques
Québec, Québec
Canada G1J 1Z4
161 entries « 17 of 17 »

Dupré N, Bouchard JP, Cossette L, Brunet D, Vanasse M, Lemieux B, Mathon G, Puymirat J

Phenotypic manifestations in French-Canadian populations with Charcot-Marie-Tooth disease type 1A associated with 17p11.2 duplication

Journal Article

Ann N Y Acad Sci, 883 , 1999.

| Links:

161 entries « 17 of 17 »
Signaler des ajouts ou des modifications

Active projects

  • Comprehensive Analysis Platform To Understand,Remedy and Eliminate ALS, from 2021-01-01 to 2025-03-31
  • Depicting disease heterogeneity in neurofibromatosis type 1 and the role of dermal fibroblasts in the establishment of microenvironment favouring NF1-associated skin tumor formation using personalized tissue-engineered 3D models, from 2023-10-01 to 2028-09-30
  • Développement d’un registre de patients sur la neurofibromatose , from 2023-08-03 to 2026-08-03
  • Digital measurement of gait as a potential pharmacodynamic/response biomarker for ALS-FTSD , from 2022-09-01 to 2025-06-30
  • Étude rétrospective sur le recours à l’aide médicale à mourir en sclérose latérale amyotrophique (SLA/AMM) au CHU de Québec-Université Laval., from 2023-10-24 to 2025-11-01
  • L'hyperhomocystéinémie:étude de son potentiel comme biomarqueur du déclin cognitif commun à la démence à corps de Lewy et à la maladie de parkinson pour améliorer le diagnostic et le traitement des patients, from 2024-01-23 to 2024-12-31
  • The Canadian Parkinson Network, from 2018-10-01 to 2024-05-30

Recently finished projects

  • Biobanque PEJ-235 , from 2023-07-25 to 2024-03-31
  • Capture ALS - Time Frame, from 2021-10-28 to 2022-10-27
  • Creating an Open Science Repository of ARCA1 iPSCs, from 2021-05-31 to 2023-05-31
  • Crosstalk between immune response and metabolic signaling: targeting leptin/AMPK axis to restore metabolic homeostasis in ALS, from 2021-02-01 to 2023-01-31
  • Depicting disease heterogeneity in neurofibromatosis type 1 and the role of microenvironment in NF1-associated skin tumor formation through personalized tissue-engineered 3D models, from 2023-03-01 to 2024-02-29
  • Développement d’une approche en santé durable pour la recherche sur le Parkinson et les troubles associés, from 2022-04-29 to 2023-04-30
  • Neuro Genomics Patnership (NGP) s’engage à couvrir tous les coûts attribuables au projet pour l’ensemble des activités menées par l’équipe de Dr Dupré relatives au Module 2 du NGP., from 2023-04-13 to 2024-04-12
  • Recherche clinique en vue de mettre en ligne le test de sévérité des commotions cérébrales et création d'un registre de participants , from 2022-11-01 to 2023-03-31
  • Reseau Parkinson Québec_RPQ / Quebec Parkinson, from 2022-04-01 to 2023-03-31
Data provided by the Université Laval research projects registery